









Markets
/
Stocks
/
nasdaq-ttnp
/

Titan Pharmaceuticals Inc

TTNP

View Detailed Chart

3.990USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

3.65MMarket Cap

LossP/E TTM



Titan Pharmaceuticals Inc

3.990

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-1.23%

5 Days

-1.97%

1 Month

-9.32%

6 Months

+20.91%

Year to Date

+22.39%

1 Year

-32.26%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(2)

Buy(1)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.143

Sell

RSI(14)

41.696

Neutral

STOCH(KDJ)(9,3,3)

20.363

Neutral

ATR(14)

0.431

High Vlolatility

CCI(14)

-109.109

Sell

Williams %R

82.424

Oversold

TRIX(12,20)

-0.137

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.092

Sell

MA10

4.372

Sell

MA20

4.421

Sell

MA50

4.473

Sell

MA100

4.201

Sell

MA200

3.974

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Ticker SymbolTTNP

CompanyTitan Pharmaceuticals Inc

CEOMr. Weei Jye Chay

Websitehttps://www.titanpharm.com/